Asymmetric dimethylarginine (ADMA): Is really a biomarker for cardiovascular prognosis?

International Journal of Cardiology

Volumn 153, Issue 2, 2011, Pages 123-125

  Tousoulis, Dimitris ^a   Siasos, Gerasimos ^a   Oikonomou, Evangelos ^a   Stougianos, Pavlos ^a   Papageorgiou, Nikolaos ^a   Papavassiliou, Athanasios G ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Asymmetric dimethylarginine; Atherosclerosis; Biomarker; Cardiovascular disease

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INDEPENDENT VARIABLE; KIDNEY FAILURE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; STABLE ANGINA PECTORIS;

ARGININE; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; REFERRAL AND CONSULTATION;

EID: 81755166362     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.070     Document Type: Editorial

References (25)

1. R.H. Böger Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond Ann Med 38 2 2006 126 136 Review
2. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography Int J Card 2011 (in press).
3. D.E. Wilcken, A.S. Sim, J. Wang, and X.L. Wang Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism Mol Genet Metab 91 4 Aug 2007 309 317
4. P. Vallance, and J. Leiper Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway Arterioscler Thromb Vasc Biol 24 2004 1023 1030
5. R.H. Boger, K. Sydow, and J. Borlak LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases Circ Res 87 2000 99 105
6. G. Siasos, D. Tousoulis, C. Antoniades, E. Stefanadi, and C. Stefanadis L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol 116 3 2007 Apr 4 300 308
7. D. Tousoulis, R.H. Böger, C. Antoniades, G. Siasos, E. Stefanadi, and C. Stefanadis Mechanisms of disease: L-arginine in coronary atherosclerosis-a clinical perspective Nat Clin Pract Cardiovasc Med 4 5 May 2007 274 283 Review
8. G. Siasos, D. Tousoulis, and C. Vlachopoulos The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance Am J Hypertens 22 6 Jun 2009 586 592
9. G. Siasos, D. Tousoulis, and C. Vlachopoulos Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals Int J Cardiol 126 3 Jun 6, 2008 394 399
10. R.H. Bger, S.M. Bode-Bger, and A. Szuba Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Circulation 98 1998 1842 1847
11. R.H. Bger, S.M. Bode-Bger, W. Thiele, W. Junker, K. Alexander, and J.C. Frlich Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease Circulation 95 1997 2068 2074
12. A. Surdacki, M. Nowicki, J. Sandmann, D. Tsikas, R.H. Bger, and S.M. Bode-Bger Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension J Cardiovasc Pharmacol 33 1999 652 658
13. J.T. Kielstein, R.H. Bger, and S.M. Bode-Bger Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease J Am Soc Nephrol 10 1999 594 600
14. M. Gorenflo, C. Zheng, E. Werle, W. Fiehn, and H.E. Ulmer Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension J Cardiovasc Pharmacol 37 2001 489 492
15. H. Miyazaki, H. Matsuoka, and J.P. Cooke Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis Circulation 99 1999 1141 1146
16. R.H. Böger, R. Maas, F. Schulze, and E. Schwedhelm Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk Pharmacol Res 60 6 Dec 2009 481 487
17. V.P. Valkonen, H. Päivä, and J.T. Salonen Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine Lancet 358 2001 2127 2128
18. F. Schulze, H. Lenzen, and C. Hanefeld Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the influence of ADMA concentration (CARDIAC) study Am Heart J 152 3 2006 493 e1-8
19. R. Schnabel, S. Blankenberg, and E. Lubos Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study Circ Res 97 2005 e53 e59
20. A. Meinitzer, U. Seelhorst, and B. Wellnitz Asymmetrical dimethylarginine independently predicts total cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study) Clin Chem 53 2007 273 283
21. C. Zoccali, S.M. Bode-Bger, F. Mallamaci, F.A. Benedetto, G. Tripepi, and L. Malatino Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD) Lancet 358 2001 2113 2117
22. T.M. Lu, Y.A. Ding, S.J. Lin, W.S. Lee, and H.C. Tai Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention Eur Heart J 24 2003 1912 1919
23. C. Dückelmann, F. Mittermayer, D.G. Haider, J. Altenberger, J. Eichinger, and M. Wolzt Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure Arterioscler Thromb Vasc Biol 27 2007 2037 2042
24. R.H. Böger, L.M. Sullivan, and E. Schwedhelm Plasma asymmetric dimethylarginine (ADMA) and incidence of cardiovascular disease and mortality in the community Circulation 119 2009 1592 1600
25. T. Leong, D. Zylberstein, and I. Graham Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg Arterioscler Thromb Vasc Biol 28 2008 961 967